JAK2 and B-cell non-Hodgkin lymphoma: In particular, JAK2 phosphorylation of EZH2 at tyrosine 641 is able to promote EZH2 degradation via the SCFβ-TrCP E3 ubiquitin ligase pathway in B cell lymphoma [24].